Behavioral Neurology & Neuropsychiatry Certification Examination Committee Contributors
Jonathan M. Silver, MD, Chair, New York University School of Medicine
Disclosures: Receives royalties for being editor of a book. Holds stock in Alnylm Pharmaceuticals.
C. Alan Anderson, MD, University of Colorado School of Medicine
Disclosures: Nothing to disclose.
David B. Arciniegas, MD, Baylor College of Medicine
Disclosures: Serves on the Medical Advisory Board for Alliance Family of Companies (dba Stratus Neuro), a company that provides in-home EEG testing and monitoring services.
Miles G. Cunningham, MD, PhD, McLean Hospital
Disclosures: Nothing to disclose.
Donald Eknoyan, MD, Kaiser Permanente
Disclosures: Nothing to disclose.
Colin J. Harrington, MD, Rhode Island Hospital
Disclosures: Nothing to disclose.
John Hart, Jr, MD, University of Texas at Dallas
Disclosures: Nothing to disclose.
Robin A. Hurley, MD, FANPA, Wake Forest School of Medicine
Disclosures: Employee of the Veterans Administration (VA). VA received research funding from Teva Pharma for posttraumatic migraine study, Aptinex, Inc for PTSD and sleep study, and Avanir Pharmaceuticals traumatic brain injury and aggression study. Role: Principal investigator. VA received research funding for the million veteran program, the MIRECC, relating to PTSD and TBI; funding for a genetics study called PRIME, and funding for a study of suvorexant for PTSD-related insomnia. No personal compensation received related to the research funding received.
Michael Schrift, DO, MA, FANPA, Northwestern University Feinberg School of Medicine
Disclosures: Nothing to disclose.
Kyle Steinman, MD, MAS, University of Washington/Seattle Children's Hospital
Disclosures: Received research funding from a government organization.